Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Roche Holding Ltd S/Adr (RHHBY)

Roche Holding Ltd S/Adr (RHHBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 378,091,456
  • Shares Outstanding, K 6,370,538
  • Annual Sales, $ 76,450 M
  • Annual Income, $ 15,542 M
  • EBIT $ 0 M
  • EBITDA $ 19,129 M
  • 60-Month Beta 0.44
  • Price/Sales 4.93
  • Price/Cash Flow 16.58
  • Price/Book 8.32
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 01/29/26
  • Annual Dividend & Yield (Fwd) 0.87 (1.46%)
  • Most Recent Dividend 0.873 on 03/28/25
  • Sector Medical
  • INDUSTRY GROUPING Large Cap Pharma

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.0200 +11.94%
on 01/28/26
60.2200 -1.44%
on 02/17/26
+4.9200 (+9.04%)
since 01/20/26
3-Month
47.4900 +24.97%
on 12/01/25
60.2200 -1.44%
on 02/17/26
+11.4300 (+23.85%)
since 11/20/25
52-Week
34.7500 +70.79%
on 04/09/25
60.2200 -1.44%
on 02/17/26
+18.2000 (+44.23%)
since 02/20/25

Most Recent Stories

More News
FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia

– First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment – – Approval expands Genentech’s...

RHHBY : 59.3500 (+0.29%)
FDA Accepts New Drug Application for Genentech’s Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer

– Filing acceptance based on Phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus...

RHHBY : 59.3500 (+0.29%)
Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease

– MAJESTY, the first global Phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years – – Up to 30% of people...

RHHBY : 59.3500 (+0.29%)
Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)

– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, Ocrevus, in reducing...

RHHBY : 59.3500 (+0.29%)
Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity

- A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p < 0.001) at 48 weeks at the highest dose tested (24 mg), without reaching...

RHHBY : 59.3500 (+0.29%)
Genentech More than Doubles Investment in Holly Springs, North Carolina Manufacturing Facility

Genentech will more than double the initial investment in a state-of-the-art biomanufacturing facility in Holly Springs to approximately $2 billion, bolstering Roche and Genentech’s...

RHHBY : 59.3500 (+0.29%)
Looking to ‘Sell America’ Amid Fed Drama? Here’s 1 ETF to Buy.

'Sell America' fear is rising again, and this non-U.S. ETF could be a wise buy to stay diversified and invested globally while U.S. policy risks swirl.

BLK : 1,093.64 (+1.14%)
BABA : 154.45 (+0.12%)
DXY00 : 97.796s (-0.13%)
SIH26 : 82.343s (+6.07%)
GCG26 : 5,059.3s (+1.68%)
NVS : 162.67 (-0.76%)
RHHBY : 59.3500 (+0.29%)
HSBC : 88.15 (+1.51%)
TSM : 370.54 (+2.82%)
ASML : 1,469.59 (+0.73%)
$DXY : 97.80 (-0.13%)
AZN : 204.20 (-1.09%)
When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology

Market rotations are as old as Wall Street itself. When capital exits overheated sectors like big tech, it often finds its way into undervalued industries ripe for rediscovery. The latest shift, away from...

AZN : 204.20 (-1.09%)
PPCB : 0.1916 (-5.48%)
RHHBY : 59.3500 (+0.29%)
BMY : 60.66 (+0.60%)
FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma

– Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute – – Availability of Lunsumio VELO allows treatment aligned to people’s clinical...

RHHBY : 59.3500 (+0.29%)
Genentech Announces Agreement With U.S. Government

– Agreement with the U.S. government addresses prescription drug costs and encourages other wealthy nations to reward biopharmaceutical innovation – – Influenza...

RHHBY : 59.3500 (+0.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its...

See More

Key Turning Points

3rd Resistance Point 60.3033
2nd Resistance Point 59.8767
1st Resistance Point 59.6133
Last Price 59.3500
1st Support Level 58.9233
2nd Support Level 58.4967
3rd Support Level 58.2333

See More

52-Week High 60.2200
Last Price 59.3500
Fibonacci 61.8% 50.4905
Fibonacci 50% 47.4850
Fibonacci 38.2% 44.4795
52-Week Low 34.7500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar